# FcRider-based Expression and Delivery of Stable Env Immunogens for HIV Vaccines

> **NIH NIH N43** · ANTAGEN PHARMACEUTICALS, INC. · 2022 · $299,998

## Abstract

Novel Platforms for Delivery and/or Expression of HIV Env Immunogens for HIV Vaccines: Efforts towards the development of an efficacious HIV vaccine have focused on improvements in the design of the HIV envelope (Env) immunogen for induction and generation of broadly neutralizing antibody (bNAb) responses and novel platforms for immunogen delivery. The goal of this program is to develop an HIV vaccine platform for delivery of HIV Env immunogens that induce bnAbs and to demonstrate that the vaccine platform/immunogen proposed will elicit a strong and durable NAb HIV Env response.

## Key facts

- **NIH application ID:** 10667354
- **Project number:** 75N93022C00011-0-9999-1
- **Recipient organization:** ANTAGEN PHARMACEUTICALS, INC.
- **Principal Investigator:** WENDA GAO
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $299,998
- **Award type:** —
- **Project period:** 2022-07-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10667354

## Citation

> US National Institutes of Health, RePORTER application 10667354, FcRider-based Expression and Delivery of Stable Env Immunogens for HIV Vaccines (75N93022C00011-0-9999-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10667354. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*